Advocacy intelligence hub — real-time data for patient organizations
Icahn School of Medicine at Mount Sinai
Apokyn: FDA approved
For the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose-wearing-off" and unpredictable :on/off" episodes) associated with advanced Parkinson's disease
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Apokyn
MDD US Operations, LLC
Apokyn
(Apomorphine HCl)Orphan drugMDD US Operations, LLC
Antonio Fontanellas
Hepatology Program
Ulrich Stölzel
Porphyrie Zentrum
Thomas Stauch, MD
Porphyrie-Speziallabor EPNET
📍 EASTON, MD
Amy K Dickey
Massachusetts General Hospital
Jia-Jia Lei
he First Clinical Medical School
Karl Elmo Anderson
University of Texas